Silence Therapeutics SLN Growth Metrics (2019-2026)

NASDAQ SLN
$10.80 -0.40 (-3.57%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Silence Therapeutics Quarterly Growth Metrics

Periods 14 quarters
Latest Jun 2026

Silence Therapeutics reported asset growth of -35.60% for the quarter ended Jun 2026. These growth metrics cover 14 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Growth Metrics Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Growth Ratios
Assets Growth (1y) 69.64%-35.13%-37.87%-35.60%
Assets (QoQ) -8.56%-10.83%-11.16%-10.46%-12.42%-7.57%
Capital Expenditures Growth (1y)Capex Growth (1y) -43.53%-95.31%
Capital Expenditures (QoQ)Capex (QoQ) -24.71%-3.13%-93.55%1,100.00%-93.75%
Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) -37.17%108.59%173.50%-35.14%4.30%80.93%-90.71%-91.28%72.63%
Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) 53.04%54.67%22.76%6.97%-44.02%
Cash & Equivalents Growth (5y)Cash & Equiv. Growth (5y) 19.38%47.50%-20.82%
Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) -46.52%-35.67%96.53%-86.25%-49.84%1,173.71%
Cash from Investing Activities Growth (1y)Cash from Investing Growth (1y) 11.07%-3,532.56%234.48%-180.66%122.53%4,257.49%
Cash from Investing Activities (QoQ)Cash from Investing (QoQ) 99.91%-88,597.67%273.37%-167.12%96.48%3,383.55%-204.00%118.75%549.40%
Cash from Operations Growth (1y)Cash from Ops. Growth (1y) -34.63%-302.74%57.41%37.05%-26.76%106.90%
Cash from Operations (QoQ)Cash from Ops. (QoQ) 40.84%-373.41%-7.32%55.21%-76.98%49.93%-58.61%9.81%109.63%
EBITDA Margin Growth (1y) -1.99M-0.77M-1.44M-3.63M1.62M
EBITDA Margin (QoQ) -0.29M0.09M0.20M-1.99M0.93M-0.58M-1.99M3.26M
EBIT Growth (1y) -409.03%-2.46%12.51%-186.33%44.61%42.14%
EBIT Margin Growth (1y) -2.00M-0.78M-1.45M-3.66M1.63M
EBIT Margin (QoQ) -0.29M0.09M0.20M-2.00M0.93M-0.58M-2.01M3.29M
EBIT (QoQ) -319.06%-28.26%85.49%-552.78%15.65%-9.52%52.52%-26.29%11.90%
EBT Growth (1y) -1,279.59%-40.03%40.96%-193.22%47.57%55.14%
EBT Margin Growth (1y) -2.01M-0.98M-1.08M-3.47M1.65M
EBT Margin (QoQ) -0.24M0.01M0.24M-2.01M0.79M-0.10M-2.14M3.11M
EBT (QoQ) -844.25%-81.77%135.57%-325.96%4.16%23.36%43.84%-27.08%17.98%
EPS (Basic) Growth (1y) -1,048.66%-37.01%41.25%-193.69%47.58%55.16%
EPS (Basic) (QoQ) -703.70%-78.66%135.22%-327.12%4.13%23.39%43.84%-27.07%17.98%
EPS (Diluted) Growth (1y) -1,048.66%-37.01%41.25%-193.69%47.58%55.16%
EPS (Diluted) (QoQ) -703.70%-78.66%135.22%-327.12%4.13%23.39%43.84%-27.07%17.98%
FCF Margin Growth (1y) -0.86M-0.91M-0.51M-5.08M0.50M
FCF Margin (QoQ) -0.06M-0.10M0.16M-0.86M-0.11M0.29M-4.40M4.72M
Free Cash Flow Growth (1y)FCF Growth (1y) -34.67%-297.38%57.50%37.19%-26.72%106.88%
Free Cash Flow (QoQ)FCF (QoQ) 39.91%-367.26%-7.29%55.30%-77.31%50.03%-58.57%9.81%109.63%
Gross Margin Growth (1y) -0.00M0.04M0.02M-0.00M0.00M
Gross Margin (QoQ) -0.04M0.02M0.02M-0.00M8.00-231.00496.000.00M
Gross Profit Growth (1y) -99.32%105.39%104.44%-99.91%367.05%
Gross Profit (QoQ) -119.98%16.92%1,186.74%-99.62%57.95%-31.65%-76.84%1,768.18%
Net Cash Flow Growth (1y)NCF Growth (1y) -176.62%-448.13%172.40%-283.26%90.11%384.62%
Net Cash Flow (QoQ)NCF (QoQ) -105.76%-1,209.58%169.11%-247.03%58.81%272.98%-274.92%92.07%1,285.88%
Net Income Growth (1y) -1,134.00%-38.47%41.04%-195.68%47.57%55.15%
Net Income (QoQ) -754.46%-79.92%134.61%-331.91%4.12%23.38%43.84%-27.08%17.98%
Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) -1,134.00%-38.47%41.04%-195.68%47.57%55.15%
Net Income towards Common Stockholders (QoQ)Net Income (QoQ) -754.46%-79.92%134.61%-331.91%4.12%23.38%43.84%-27.08%17.98%
Net Margin Growth (1y) -2.01M-0.97M-1.08M-3.47M1.65M
Net Margin (QoQ) -0.25M0.01M0.24M-2.01M0.79M-0.10M-2.14M3.11M
Operating Income Growth (1y)Op. Inc Growth (1y) -409.03%-2.46%12.51%-186.33%44.61%42.14%
Operating Income (QoQ)Op. Inc (QoQ) -319.06%-28.26%85.49%-552.78%15.65%-9.52%52.52%-26.29%11.90%
Operating Margin Growth (1y) -2.00M-0.78M-1.45M-3.66M1.63M
Operating Margin (QoQ) -0.29M0.09M0.20M-2.00M0.93M-0.58M-2.01M3.29M
Profit After Tax Growth (1y)PAT Growth (1y) -1,134.00%-38.47%41.04%-195.68%47.57%55.15%
Profit After Tax (QoQ)PAT (QoQ) -754.46%-79.92%134.61%-331.91%4.12%23.38%43.84%-27.08%17.98%
Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) -33.71%89.43%76.09%-1.49%-12.84%-19.21%-13.04%-17.54%-25.35%
Property, Plant & Equipment (Net) Growth (3y)PP&E (Net) Growth (3y) 30.28%48.67%14.78%-11.47%-15.08%
Property, Plant & Equipment (Net) Growth (5y)PP&E (Net) Growth (5y) 13.68%18.27%1.22%
Property, Plant & Equipment (Net) (QoQ)PP&E (Net) (QoQ) -6.88%4.84%-6.76%-4.47%-11.70%-5.09%
Return on Assets [ROA] Growth (1y)ROA Growth (1y) -0.00M-898.00
Return on Assets [ROA] (QoQ)ROA (QoQ) -827.00378.00-0.00M283.00674.00
Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) -0.00M-0.00M
Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) -472.00-581.00-0.00M308.00-17.00
Return on Equity [ROE] Growth (1y)ROE Growth (1y) -0.01M-0.01M-0.01M
Return on Equity [ROE] (QoQ)ROE (QoQ) -0.00M-0.00M-25.00-0.01M-439.00-210.00
Return on Sales [ROS] Growth (1y)ROS Growth (1y) -2.00M-0.78M-1.45M-3.66M1.63M-0.04M
Return on Sales [ROS] (QoQ)ROS (QoQ) -0.29M0.09M0.20M-2.00M0.93M-0.58M-2.01M3.29M-0.74M
Revenue Growth (1y) -99.10%-72.00%-89.39%-99.87%197.18%
Revenue (QoQ) -94.90%87.25%1,589.25%-99.44%57.75%-29.02%-78.62%1,141.18%
Share-based Compensation Growth (1y)Stock Comp. Growth (1y) -14.04%-49.65%-37.67%-102.16%-30.88%-37.27%
Share-based Compensation (QoQ)Stock Comp. (QoQ) 0.56%-1.79%-2.11%-11.08%-41.10%21.58%-103.39%2,945.35%-46.55%

Silence Therapeutics Growth Metrics API

Pull Silence Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SLN&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY